ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer
Crossref DOI link: https://doi.org/10.1245/s10434-019-08057-5
Published Online: 2019-11-06
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nakazawa, Nobuhiro
Yokobori, Takehiko
Turtoi, Andrei
Shirabe, Ken
Text and Data Mining valid from 2019-11-06
Version of Record valid from 2019-11-06
Article History
Received: 15 October 2019
First Online: 6 November 2019
Disclosures
: None of the authors have conflicts of interest to disclose.